DOCSLIB.ORG

Scientific & Poster Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Scientific & Poster Abstracts THURSDAY CONCURRENT SESSION #1 at baseline, week 12 and months 6, 9 and 12. Changes from baseline to month 12 in lipid and coagulation parameters, blood glucose, and cardiovascular events are summarized descriptively. Results: 1835 women were randomized and took ≥1 capsule of daily S-1. E2/P4 (mg/mg) of 1/100 (n=415), 0.5/100 (n=424), 0.5/50 (n=421), 0.25/50 (n=424) or Effects of Hormone Therapy on Heart Fat and Atherosclerosis placebo (n=151). Total cholesterol and LDL-cholesterol levels numerically decreased Progression in Recently Postmenopausal Women from KEEPS Trial from baseline to month 12, HDL-cholesterol levels remained similar to baseline and Samar R. El Khoudary, PhD, MPH1, Qian Zhao1, JoAnn E. Manson2, Maria M. Brooks1, triglycerides levels increased (Table). Few women had triglycerides and cholesterol Nanette Santoro3, Dennis M. Black4, Mitchell Harman7, Marcelle I. Cedars4, Paul N. increases (≥50 mg/dL or above normal levels) at 12 months with TX-001HR (6-11% and Hopkins8, Ann E. Kearns6, Virginia Miller6, Hugh S. Taylor9, Matthew J. Budoff5. 1-4%, respectively) vs placebo (7% and 3%). Fasting glucose levels remained similar 1University of Pittsburgh, Pittsburgh, PA; 2Harvard Medical School and Brigham and to baseline at 12 months. Antithrombin activity and factor XIV and protein S levels Women’s Hospital, Boston, MA; 3University of Colorado, Aurora, CO; 4University tended to decrease from baseline compared with placebo, and time for activated partial of California San Francisco, San Francisco, CA; 5Los Angeles Biomedical Research thromboplastin, prothrombin time, fibrinogen levels and prothrombin international Institute, Torrance, CA; 6Mayo Clinic, Rochester, MN; 7Phoenix Veterans Affairs normalized ratio remained similar to baseline at 12 months. Two women experienced Health Care System, Phoenix, AZ; 8University of Utah Health, Salt Lake City, UT; “coronary heart disease” adverse events considered not related to treatment: unstable 9Yale University, New Haven, CT angina in one subject (E2/P4 0.5/50), and angina and coronary artery disease in Objective: Heart fat depots, within [epicardial adipose tissue (EAT)] and outside another (E2/P4 1/100). The woman who experienced unstable angina also experienced [paracardial adipose tissue (PAT)] the pericardium, have been linked to increased subarachnoid hemorrhage and cerebellar infarction, neither considered treatment related. cardiovascular disease risk. Postmenopausal women have greater volumes of heart fat One case of deep vein thrombosis (DVT) with E2/P4 0.5/50 was reported in a woman than premenopausal women. Recent evidence suggests a role of endogenous estrogen with a family history of DVT. Conclusion: Twelve months of TX-001HR treatment in in heart fat accumulation, possibly limited to PAT. The impact of hormone therapy menopausal women with VMS and an intact uterus had minimal clinically meaningful (HT) on heart fat buildup is unknown. We evaluated the differential effects of HT effects on lipid, glucose, or coagulation parameters. Observed changes in triglyceride on the accumulation of heart fat depots and their associations with coronary artery levels, antithrombin activity, factor XIV, and protein S were consistent with oral estrogen calcification (CAC) progression in recently postmenopausal women. Design: KEEPS therapy. Although this trial lacked statistical power to assess these outcomes, VTE rates, was a multi-center, randomized, clinical trial of the effects of oral conjugated equine cardiovascular disease, and cerebrovascular events were as expected for a postmenopausal estrogens (o-CEE) and transdermal 17β-estradiol (t-E2), both with progesterone, population. If approved, TX-001HR may provide the first oral combination of E2/P4 for compared to placebo, on 48-month subclinical atherosclerosis progression in recently the treatment of VMS in menopausal women with a uterus. postmenopausal women. Heart fat volumes and CAC were measured on CT scans at Sources of Funding: TherapeuticsMD baseline and 48 months later. Significant CAC progression was defined as present if (1) baseline CAC score = 0 and 48 month CAC Agatston score >0 ; (2) baseline CAC score >0 to <100 and annualized change in CAC score ≥10 ; or (3) baseline CAC score ≥100 and annualized percent change in CAC score ≥10%. Changes in heart fat depots were tested using Wilcoxon signed test and compared by treatment group using Kruskal– Wallis test. Associations between change in heart fat volumes and CAC progression as well as effect modification by HT type were tested using logistic regression adjusting for age, race, study site, education, physical activity, smoking, alcohol intake, lipids, systolic blood pressure, waist circumference, anti-hypertensive medications and baseline heart fat volume. Results: Of 727 randomly assigned women, 474 [mean age (SD): 52.7(2.6); 78.1% White] had heart fat volumes and CAC scores at baseline and 48 months. EAT volume increased significantly over time in the placebo group [median (Q1, Q3): 2.12(-4.58, 6.36) cm3, P=0.003] but not in the o-CEE [-0.05(-5.93, 6.12) cm3, P>0.99] or the t-E2 group [1.68(-4.07, 4.91) cm3, P=0.07]. PAT volume did not change significantly in any group. Changes in EAT and PAT did not vary by treatment group. KEEPS only included women whose screening CAC score was < 50, resulting in 88.4% of participants having CAC=0 at baseline. At 48 month CAC progressed in 14% of the study participants. Changes in EAT and PAT were not significantly associated with CAC progression overall. However, assigned treatment significantly modified the association between changes in PAT and CAC progression in adjusted model, P=0.02, such that changes in PAT were associated with greater CAC progression risk only in t-E2 group [OR (95% CI) per 1 SD of PAT change: 2.8(1.3, 5.9)]. Conclusion: There was no significant difference among treatment groups in 48 month changes of heart fat depots. However, there was a suggestion that O-CEE slowed progress on heart fat accumulation, although not in the t-E2 group. Greater PAT changes were associated with greater CAC progression risk only in the t-E2 group. The current findings support the notion that EAT and PAT are distinct fat depots and suggest a complex role of HT in the accumulation of heart fat depots and their associations with CAC progression in recently postmenopausal women. Sources of Funding: KEEPS: Aurora Foundation to the Kronos Longevity Research Institute, NIH P50 AG 44170 to VMM, 1 UL1 RR024150, Mayo CTSA 1 UL1 RR024150, the Mayo Foundation, CTSA UL1 RR024139, UL1 RR024131 from the NCRR. Study medications: supplied in part by Bayer Health Care and by Abbott aPTT: activated partial thromboplastin time; INR: international normalized Pharmaceuticals. The ClinicalTrials.gov number is NCT00154180. KEEPS Heart Fat ratio. Ancillary study: NHLBI R21HL140011. S-3. S-2. Evaluation of Systemic Effects of a Vaginal Estradiol Softgel Capsule Effects of Single-Capsule 17β-Estradiol/Progesterone (TX-001HR) on (TX-004HR) in Menopausal Women with Moderate-to-Severe Dyspareunia Metabolic Parameters and Cardiovascular Outcomes in Menopausal Lisa C. Larkin MD, MD5, Andrew M. Kaunitz, MD1, James Liu, MD2, Shelli Graham, Women of the REPLENISH Trial PhD3, Brian Bernick, MD3, Sebastian Mirkin, MD3, Ginger Constantine4. 1University Rogerio Lobo, MD1, James Liu, MD2, Andrew M. Kaunitz, MD3, Brian Bernick, MD4, of Florida College of Medicine-Jacksonville, Jacksonville, FL; 2University Hospitals Shelli Graham, PhD4, Ginger Constantine5, Sebastian Mirkin, MD4. 1Columbia University Cleveland Medical Center, Cleveland, OH; 3TherapeuticsMD, Boca Raton, FL; Medical Center, New York, NY; 2University Hospital Cleveland Medical Center, 4EndoRheum Consultants, LLC, Malvern, PA; 5Lisa Larkin MD and Associates, Cleveland, OH; 3University of Florida College of Medicine-Jacksonville, Jacksonville, Mariemont, OH FL; 4TherapeuticsMD, Boca Raton, FL; 5EndoRheum Consultants, LLC, Malvern, PA Objective: TX-004HR (an investigational, vaginal softgel capsule of low-dose, Objective: TX-001HR (TherapeuticsMD, Boca Raton, FL), an investigational product solubilized 17β-estradiol, designed to be mucoadhesive and rapidly dissolving) that combines 17β-estradiol and progesterone (E2/P4) in a single, oral softgel capsule, significantly improved vaginal physiology and dyspareunia (primary endpoints) as well as significantly reduced the frequency and severity of moderate-to-severe vasomotor dryness (secondary enpoint) in menopausal women with moderate-to-severe dyspareunia symptoms (VMS) in menopausal women of the REPLENISH trial (Lobo et al, Obstet as their most bothersome symptom in the phase 3 REJOICE trial (NCT02253173).1 Gynecol 2018, in press). The objective of this report is to summarize safety endpoints Improvements were achieved with negligible to very low systemic absorption of related to metabolic parameters and cardiovascular outcomes from REPLENISH. estradiol with doses of 4 µg, 10 µg and 25 µg (the 4 µg and 10 µg doses have been Design: REPLENISH (NCT01942668) was a phase 3, randomized, double-blind, submitted for FDA approval).2 Systemic levels of estradiol with 10 µg and 25 µg doses placebo-controlled, multicenter trial that evaluated 4 TX-001HR doses vs placebo in were shown to be lower than with the same doses of a commercially available vaginal menopausal women (40-65 years) with a uterus. Women were randomized to E2/P4 estradiol tablet (Vagifem®) in head-to-head studies.3 This report summarizes the effects doses or placebo in a proportion
Load more

Recommended publications
  • Al Exposure Increases Proline Levels by Different Pathways in An
    www.nature.com/scientificreports OPEN Al exposure increases proline levels by diferent pathways in an Al‑sensitive and an Al‑tolerant rye genotype Alexandra de Sousa1,2, Hamada AbdElgawad2,4, Fernanda Fidalgo1, Jorge Teixeira1, Manuela Matos3, Badreldin A. Hamed4, Samy Selim5, Wael N. Hozzein6, Gerrit T. S. Beemster2 & Han Asard2* Aluminium (Al) toxicity limits crop productivity, particularly at low soil pH. Proline (Pro) plays a role in protecting plants against various abiotic stresses. Using the relatively Al‑tolerant cereal rye (Secale cereale L.), we evaluated Pro metabolism in roots and shoots of two genotypes difering in Al tolerance, var. RioDeva (sensitive) and var. Beira (tolerant). Most enzyme activities and metabolites of Pro biosynthesis were analysed. Al induced increases in Pro levels in each genotype, but the mechanisms were diferent and were also diferent between roots and shoots. The Al‑tolerant genotype accumulated highest Pro levels and this stronger increase was ascribed to simultaneous activation of the ornithine (Orn)‑biosynthetic pathway and decrease in Pro oxidation. The Orn pathway was particularly enhanced in roots. Nitrate reductase (NR) activity, N levels, and N/C ratios demonstrate that N‑metabolism is less inhibited in the Al‑tolerant line. The correlation between Pro changes and diferences in Al‑sensitivity between these two genotypes, supports a role for Pro in Al tolerance. Our results suggest that diferential responses in Pro biosynthesis may be linked to N‑availability. Understanding the role of Pro in diferences between genotypes in stress responses, could be valuable in plant selection and breeding for Al resistance. Proline (Pro) is involved in a wide range of plant physiological and developmental processes1.
    [Show full text]
  • Recapturing Our Identity Through Arts and Crafts" Event to Make Sure That Doesn't Occur
    Rez Car Show Teaching Hammock Youth Conference “Looking Back at the Seminole Trail” Page 3 Page 13 Page 14 Presort Standard U.S. Postage Paid S. Florida, FL Permit No. 1624 “Voice of the Unconquered” 50¢ www.seminoletribe.com Volume XXIV • Number 11 August 15, 2003 2003-2004 Seminole Princesses Hollywood Youth Conference Visits Historical Sites “Looking Back at the Seminole Trail” ORLANDO — Members of the Hollywood Youth Conference journeyed back in time, visiting the historic grounds of Fort King, Castillo de San Marcos, and the infamous Dade Battlefield. "Looking Back at the Seminole Trail" offered Seminoles a look into their distinguished past. From July 7 through 11, Children and adults learned about the brave warriors who refused to relin- quish their land, their homes, and their way of life. The Seminoles fought back against the U.S. Army and never signed a treaty, which is why the Seminoles are known as "The Unconquered." On Tuesday July 8, Chairman Mitchell Cypress, President Moses B. Osceola, Hollywood Council Representative Max B. Osceola, and Michael Kelly Hollywood Board Representative David DeHass Dan Osceola prefers using cypress wood for his carvings. spoke to everyone in attendance. They stressed the importance of the Youth Conference and wanted each and everyone to get something out of it. "As a youth, we didn't get much of a chance to see all these historic sites. We only read about Recapturing Our them. You all have the opportunity to see history," said Mitchell Cypress. Moses Osceola stated, "The staff has planned Identity Through some great things for you this week.
    [Show full text]
  • Formaldehyde? Formaldehyde Is a Colorless, Strong-Smelling Gas Used to Make Household Products and Building Materials, Furniture, and Paper Products
    What is formaldehyde? Formaldehyde is a colorless, strong-smelling gas used to make household products and building materials, furniture, and paper products. It is used in particleboard, plywood, and fiberboard. What products contain formaldehyde? Formaldehyde can be found in most homes and buildings. Formaldehyde is also released into the air from many products you may use in your home. Because formaldehyde breaks down in air, you may breathe it in from such products as • carpet cleaner • gas cookers and open fireplaces, • cosmetics, • glue, • fabric softeners, • household cleaners, and • fingernail polish and hardeners, • latex paint. Burning cigarettes and other tobacco products also release formaldehyde. Products give off different amounts of formaldehyde. For example, • fingernail polish gives off more formaldehyde than do plywood and new carpet, and • some paper products—such as grocery bags and paper towels—give off only small amounts of formaldehyde. Our bodies even produce some formaldehyde, although only in small amounts. Will I get sick if I breathe or touch formaldehyde? You might not get sick if you breathe or touch formaldehyde, but if you have breathed or touched formaldehyde you may have symptoms such as • sore, itchy, or burning eyes, nose, or throat; • skin rash; or • breathing symptoms such as chest tightness, coughing, and shortness of breath. People who are more likely to get sick from being around formaldehyde are children, the elderly, and people with asthma. Formaldehyde may affect children more than it does adults. If you think your child may have been around formaldehyde, and he or she has symptoms contact a doctor. You should also know that: babies are not likely to get formaldehyde from breast milk, and you may be more sensitive to formaldehyde if you have asthma.
    [Show full text]
  • Method 323—Measurement of Formaldehyde Emissions from Natural Gas-Fired Stationary Sources—Acetyl Acetone Derivitization Method
    While we have taken steps to ensure the accuracy of this Internet version of the document, it is not the official version. Please refer to the official version in the FR publication, which appears on the Government Printing Office's FDSys website (http://www.gpo.gov/fdsys/browse/collectionCfr.action?). Method 323—Measurement of Formaldehyde Emissions From Natural Gas-Fired Stationary Sources—Acetyl Acetone Derivitization Method 1.0 Introduction. This method describes the sampling and analysis procedures of the acetyl acetone colorimetric method for measuring formaldehyde emissions in the exhaust of natural gas-fired, stationary combustion sources. This method, which was prepared by the Gas Research Institute (GRI), is based on the Chilled Impinger Train Method for Methanol, Acetone, Acetaldehyde, Methyl Ethyl Ketone, and Formaldehyde (Technical Bulletin No. 684) developed and published by the National Council of the Paper Industry for Air and Stream Improvement, Inc. (NCASI). However, this method has been prepared specifically for formaldehyde and does not include specifications (e.g., equipment and supplies) and procedures (e.g., sampling and analytical) for methanol, acetone, acetaldehyde, and methyl ethyl ketone. To obtain reliable results, persons using this method should have a thorough knowledge of at least Methods 1 and 2 of 40 CFR part 60, appendix A–1; Method 3 of 40 CFR part 60, appendix A–2; and Method 4 of 40 CFR part 60, appendix A–3. 1.1 Scope and Application 1.1.1 Analytes. The only analyte measured by this method is formaldehyde (CAS Number 50–00–0). 1.1.2 Applicability. This method is for analyzing formaldehyde emissions from uncontrolled and controlled natural gas-fired, stationary combustion sources.
    [Show full text]
  • Toxicological Profile for Formaldehyde
    TOXICOLOGICAL PROFILE FOR FORMALDEHYDE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry July 1999 FORMALDEHYDE ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. FORMALDEHYDE iii UPDATE STATEMENT Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 FORMALDEHYDE vii QUICK REFERENCE FOR HEALTH CARE PROVIDERS Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions. Primary Chapters/Sections of Interest Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure. Chapter 2: Health Effects: Specific health effects of a given hazardous compound are reported by route of exposure, by type of health effect (death, systemic, immunologic, reproductive), and by length of exposure (acute, intermediate, and chronic).
    [Show full text]
  • 1.0 Introduction. This Method Describes the Sampling and Analysis Procedures of the Acetyl Acetone Colorimetric Method For
    Method 323 8/7/2017 While we have taken steps to ensure the accuracy of this Internet version of the document, it is not the official version. To see a complete version including any recent edits, visit: https://www.ecfr.gov/cgi-bin/ECFR?page=browse and search under Title 40, Protection of Environment. METHOD 323—MEASUREMENT OF FORMALDEHYDE EMISSIONS FROM NATURAL GAS-FIRED STATIONARY SOURCES—ACETYL ACETONE DERIVITIZATION METHOD 1.0 Introduction. This method describes the sampling and analysis procedures of the acetyl acetone colorimetric method for measuring formaldehyde emissions in the exhaust of natural gas-fired, stationary combustion sources. This method, which was prepared by the Gas Research Institute (GRI), is based on the Chilled Impinger Train Method for Methanol, Acetone, Acetaldehyde, Methyl Ethyl Ketone, and Formaldehyde (Technical Bulletin No. 684) developed and published by the National Council of the Paper Industry for Air and Stream Improvement, Inc. (NCASI). However, this method has been prepared specifically for formaldehyde and does not include specifications (e.g., equipment and supplies) and procedures (e.g., sampling and analytical) for methanol, acetone, acetaldehyde, and methyl ethyl ketone. To obtain reliable results, persons using this method should have a thorough knowledge of at least Methods 1 and 2 of 40 CFR part 60, appendix A-1; Method 3 of 40 CFR part 60, appendix A-2; and Method 4 of 40 CFR part 60, appendix A-3. 1.1 Scope and Application 1.1.1 Analytes. The only analyte measured by this method is formaldehyde (CAS Number 50- 00-0). 1.1.2 Applicability.
    [Show full text]
  • World Boxing Association Gilberto Mendoza President Official Ratings As of February 2000
    WORLD BOXING ASSOCIATION GILBERTO MENDOZA PRESIDENT OFFICIAL RATINGS AS OF FEBRUARY 2000 CHAIRMAN GILBERTO MENDOZA FAX: (58-44) 633177 P.O. BOX 377 MARACAY 2101-A VICE CHAIRMAN MEMBERS EDO. ARAGUA - VENEZUELA JORGE H. KLEE FAX: (57-3) 58-0621 PHONE:(44) 63-1584 STANLEY CHRISTODOLOU CBA (SOUTH AFRICA) 63-3347 JOSE EMILIO GRAGLIA FEDELATIN (ARGENTINA) FAX: (44) 63-3177 ANIBAL MIRAMONTES NABA (USA) 63-8576 ALAN KIM PABA (KOREA) E-mail: [email protected] SHIGERU KOJIMA JBC (JAPAN) http://www.wbaonline.com/ HEAVYWEIGHT (Over 190 Lbs / Over 86.18 Kgs) CRUISERWEIGHT (190 Lbs / 86.18 Kgs) LIGHT HEAVYWEIGHT (175 Lbs / 79.38 Kgs) World Champion: LENNOX LEWIS G.B World Champion: FABRICE TIOZZO FRA World Champion: ROY JONES USA Won Title: 11-13-99 Won Title: 11-08-97 Won Title: 07-18- 98 Last Mandatory: Last Mandatory: 11-14-98 Last Mandatory: Last Defense: Last Defense: 11-13-99 Last Defense: 01-15-2000 WBC: LENNOX LEWIS - IBF: LENNOX LEWIS WBC: JUAN C. GOMEZ - IBF: VASILI JIROV WBC ROY JONES - IBF: ROY JONES WBO: VITALI KLITSCHKO WBO: JOHNNY NELSON WBO: DARIUSZ MICHALCZEWSKY 1. JOHN RUIZ (WBANA) USA 1. VIRGIL HILL USA 1. RICHARD HALL INTERIM CHAMP USA 2. EVANDER HOLYFIELD USA 2. VALERY VIKHOR (PABA) LAT 2. LOUIS DEL VALLE USA 3. WLADIMIR KLITSCHKO (WBAI-EBU) UKR 3. ALEXANDER GUROV (WBAI) UKR 3. FRANK LILES USA 4. MIKE TYSON USA 4. JAMES TONEY USA 4. DERRICK HARMON (USBA) USA 5. MICHAEL GRANT (NABF) USA 5. IMAMU MAYFIELD USA 5. ERIC HARDIN USA 6. DAVID TUA (USBA) N.Z 6.
    [Show full text]
  • Targeting Glycine Reuptake in Alcohol Seeking and Relapse
    JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. TITLE PAGE Targeting Glycine Reuptake in Alcohol Seeking and Relapse Valentina Vengeliene, Martin Roßmanith, Tatiane T. Takahashi, Daniela Alberati, Berthold Behl, Anton Bespalov, Rainer Spanagel Downloaded from The primary laboratory of origin: Institute of Psychopharmacology, Central Institute of jpet.aspetjournals.org Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; at ASPET Journals on September 30, 2021 VV, MR, TTT, RS: Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; DA: Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland; BB, AB: Department of Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany; AB: Department of Psychopharmacology, Pavlov Medical University, St Petersburg, Russia JPET #244822 JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. RUNNING TITLE GlyT1 in Alcohol Seeking and Relapse Corresponding author with complete address: Valentina Vengeliene, Institute of Psychopharmacology, Central Institute of Mental Health (CIMH), J5, 68159 Mannheim, Germany Email: [email protected], phone: +49-621-17036261; fax: +49-621- Downloaded from 17036255 jpet.aspetjournals.org The number of text pages: 33 Number of tables: 0 Number of figures: 6 Number of references: 44 at ASPET Journals on September 30, 2021 Number of words in the Abstract: 153 Number of words in the Introduction: 729 Number of words in the Discussion: 999 A recommended section assignment to guide the listing in the table of content: Drug Discovery and Translational Medicine 2 JPET #244822 JPET Fast Forward.
    [Show full text]
  • Lyonia Preserve Plant Checklist
    Lyonia Preserve Plant Checklist Volusia County, Florida Aceraceae (Maple) Asteraceae (Aster) Red Maple Acer rubrum Bitterweed Helenium amarum Blackroot Pterocaulon virgatum Agavaceae (Yucca) Blazing Star Liatris sp. Adam's Needle Yucca filamentosa Blazing Star Liatris tenuifolia Nolina Nolina brittoniana Camphorweed Heterotheca subaxillaris Spanish Bayonet Yucca aloifolia Cudweed Gnaphalium falcatum Dog Fennel Eupatorium capillifolium Amaranthaceae (Amaranth) Dwarf Horseweed Conyza candensis Cottonweed Froelichia floridana False Dandelion Pyrrhopappus carolinianus Fireweed Erechtites hieracifolia Anacardiaceae (Cashew) Garberia Garberia heterophylla Winged Sumac Rhus copallina Goldenaster Pityopsis graminifolia Goldenrod Solidago chapmanii Annonaceae (Custard Apple) Goldenrod Solidago fistulosa Flag Paw paw Asimina obovata Goldenrod Solidago spp. Mohr's Throughwort Eupatorium mohrii Apiaceae (Celery) Ragweed Ambrosia artemisiifolia Dollarweed Hydrocotyle sp. Saltbush Baccharis halimifolia Spanish Needles Bidens alba Apocynaceae (Dogbane) Wild Lettuce Lactuca graminifolia Periwinkle Catharathus roseus Brassicaceae (Mustard) Aquifoliaceae (Holly) Poorman's Pepper Lepidium virginicum Gallberry Ilex glabra Sand Holly Ilex ambigua Bromeliaceae (Airplant) Scrub Holly Ilex opaca var. arenicola Ball Moss Tillandsia recurvata Spanish Moss Tillandsia usneoides Arecaceae (Palm) Saw Palmetto Serenoa repens Cactaceae (Cactus) Scrub Palmetto Sabal etonia Prickly Pear Opuntia humifusa Asclepiadaceae (Milkweed) Caesalpinceae Butterfly Weed Asclepias
    [Show full text]
  • Amino Acid Catalyzed Direct Asymmetric Aldol Reactions: a Bioorganic Approach to Catalytic Asymmetric Carbon-Carbon Bond-Forming Reactions
    5260 J. Am. Chem. Soc. 2001, 123, 5260-5267 Amino Acid Catalyzed Direct Asymmetric Aldol Reactions: A Bioorganic Approach to Catalytic Asymmetric Carbon-Carbon Bond-Forming Reactions Kandasamy Sakthivel, Wolfgang Notz, Tommy Bui, and Carlos F. Barbas III* Contribution from The Skaggs Institute for Chemical Biology and the Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037 ReceiVed January 3, 2001 Abstract: Direct asymmetric catalytic aldol reactions have been successfully performed using aldehydes and unmodified ketones together with commercially available chiral cyclic secondary amines as catalysts. Structure- based catalyst screening identified L-proline and 5,5-dimethyl thiazolidinium-4-carboxylate (DMTC) as the most powerful amino acid catalysts for the reaction of both acyclic and cyclic ketones as aldol donors with aromatic and aliphatic aldehydes to afford the corresponding aldol products with high regio-, diastereo-, and enantioselectivities. Reactions employing hydroxyacetone as an aldol donor provide anti-1,2-diols as the major product with ee values up to >99%. The reactions are assumed to proceed via a metal-free Zimmerman- Traxler-type transition state and involve an enamine intermediate. The observed stereochemistry of the products is in accordance with the proposed transition state. Further supporting evidence is provided by the lack of nonlinear effects. The reactions tolerate a small amount of water (<4 vol %), do not require inert reaction conditions and preformed enolate equivalents, and can be conveniently performed at room temperature in various solvents. In addition, reaction conditions that facilitate catalyst recovery as well as immobilization are described. Finally, mechanistically related addition reactions such as ketone additions to imines (Mannich- type reactions) and to nitro-olefins and R,â-unsaturated diesters (Michael-type reactions) have also been developed.
    [Show full text]
  • Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors
    Neurochemical Research (2019) 44:735–750 https://doi.org/10.1007/s11064-018-02712-1 REVIEW PAPER Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors Sumit Barua1 · Jong Youl Kim1 · Jae Young Kim1 · Jae Hwan Kim4 · Jong Eun Lee1,2,3 Received: 15 October 2018 / Revised: 19 December 2018 / Accepted: 24 December 2018 / Published online: 4 January 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract The central nervous system (CNS) is the most injury-prone part of the mammalian body. Any acute or chronic, central or peripheral neurological disorder is related to abnormal biochemical and electrical signals in the brain cells. As a result, ion channels and receptors that are abundant in the nervous system and control the electrical and biochemical environment of the CNS play a vital role in neurological disease. The N-methyl-D-aspartate receptor, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid receptor, kainate receptor, acetylcholine receptor, serotonin receptor, α2-adrenoreceptor, and acid-sensing ion channels are among the major channels and receptors known to be key components of pathophysiological events in the CNS. The primary amine agmatine, a neuromodulator synthesized in the brain by decarboxylation of L-arginine, can regu- late ion channel cascades and receptors that are related to the major CNS disorders. In our previous studies, we established that agmatine was related to the regulation of cell differentiation, nitric oxide synthesis, and murine brain endothelial cell migration, relief of chronic pain, cerebral edema, and apoptotic cell death in experimental CNS disorders.
    [Show full text]
  • Flavor Masking/Enhancement
    T,&YJJIVMRK %RMQEP*IIHW *PEZSV1EWOMRK)RLERGIQIRX 'LIQMGEP-RXIVQIHMEXI ® §%7MQTPI%QMRS%GMH [MXL'SQTPI\*YRGXMSREPMX] Glycine, also known as aminoacetic acid, is the simplest amino acid. Found naturally in many foods, glycine is also synthesized in the human body, where, among other functions, it helps improve glycogen storage, is utilized in the synthesis of hemoglobin, collagen, and glutathione, and facilitates the amelioration of high blood fat and uric acid levels. In addition to the important metabolic functions glycine &YJJIVMRKT,7XEFMPM^EXMSR performs, this versatile substance is widely used in With acidic and basic properties in the same molecule, a range of applications, such as flavor enhancers and glycine acts to buffer or stabilize the pH of those maskers, pH buffers and stabilizers, ingredients in phar- systems containing it. Many of the uses for glycine maceutical products, and as a chemical intermediate. depend on this ability. Glycine’s efficiency in stabilizing pH has resulted in %X,SQIMRE,SWXSJ%TTPMGEXMSRW its wide usage as a buffering agent in many pharma- ceutical products. Antacid and analgesic products are often formulated with glycine to stabilize the acidity *PEZSV1EWOMRK*PEZSV)RLERGIQIRX of the digestive tract and prevent hyperacidity. Glycine Glycine has a refreshingly sweet taste, and is one and a has been shown to promote the gastric absorption of half times as sweet as sugar. In addition to its sweetness, certain drugs, including aspirin. glycine also has the ability to mellow saltiness and bit- terness. The bitter after-taste of saccharin, for example, When formulated in an aluminum-zirconium is masked by glycine. Carbonated soft drinks and flavor tetrachlorohydrex complex, glycine buffers the high concentrates based on saccharin may contain up to 0.2 acidity of active ingredients in antiperspirants.
    [Show full text]